ARCHIVES

Five Year Survival Up To 48 Percent; DeVita Has “No Doubt” It Is Really Over 50 Percent Now

This article is from The Cancer Letter archive.

Vol. 09 No. 46 | December 2, 1983

Download PDF Visit The Full Archive

Related Articles

XGEVA not Inferior to Zometa In 1,776-Patient Phase III Study

March 25, 2011

Treatment Division Outlines Future Program Areas

January 24, 1975

FDA Approves Large-Volume Processor For Cytyc’s ThinPrep Pap Test Samples.

June 30, 2000

Mammography Guidelines Tightened For BCDDP; September Consensus Meeting Planned

May 13, 1977

NCI to Fund Research Collaboration At HMOs, Health Care Provider Networks

July 11, 1997

ADT Does Not Raise Risk of Heart Attacks In Men With No History Of Heart Disease

November 25, 2011